iX Biopharma Income Statement

Financials in millions SGD. Fiscal year is July - June.

Millions SGD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	7.77	5.96	5.91	14.39	1.75
Revenue Growth (YoY)	30.34%	0.78%	-58.91%	724.64%	77.16%
Cost of Revenue	5.73	4.91	3.59	2.1	2.13
Gross Profit	2.04	1.05	2.32	12.29	-0.38
Selling, General & Admin	6.69	6.71	9.04	9.46	8.3
Research & Development	1.64	1.73	2.82	2.33	2.75
Operating Expenses	8.33	8.54	11.86	11.79	11.05
Operating Income	-6.29	-7.5	-9.54	0.5	-11.43
Interest Expense	-0.33	-0.44	-0.27	-0.2	-0.17
Interest & Investment Income	0.02	0.03	0.01	-	0.01
Currency Exchange Gain (Loss)	-3.4	0.08	-2.77	-1.91	1.8
Other Non Operating Income (Expenses)	-0.14	0.35	1.12	0.74	1.57
EBT Excluding Unusual Items	-10.14	-7.47	-11.46	-0.88	-8.23
Gain (Loss) on Sale of Investments	-0.01	-2.51	1.74	-3.26	-
Other Unusual Items	-	-	0.01	0.04	-
Pretax Income	-10.14	-9.99	-9.71	-4.1	-8.23
Income Tax Expense	0	0.81	-0.09	0.5	0
Earnings From Continuing Operations	-10.14	-10.79	-9.62	-4.6	-8.23
Net Income	-10.14	-10.79	-9.62	-4.6	-8.23
Net Income to Common	-10.14	-10.79	-9.62	-4.6	-8.23
Shares Outstanding (Basic)	877	767	765	746	693
Shares Outstanding (Diluted)	877	767	765	746	693
Shares Change (YoY)	14.25%	0.33%	2.51%	7.60%	7.13%
EPS (Basic)	-0.01	-0.01	-0.01	-0.01	-0.01
EPS (Diluted)	-0.01	-0.01	-0.01	-0.01	-0.01
Free Cash Flow	-3.96	-6.83	-8.36	2.92	-8.91
Free Cash Flow Per Share	-0.01	-0.01	-0.01	0.00	-0.01
Gross Margin	26.27%	17.59%	39.24%	85.41%	-21.89%
Operating Margin	-80.92%	-125.78%	-161.41%	3.48%	-654.96%
Profit Margin	-130.56%	-181.14%	-162.61%	-31.95%	-471.86%
Free Cash Flow Margin	-50.97%	-114.57%	-141.30%	20.31%	-510.32%
EBITDA	-5.87	-7.08	-9.04	1.15	-10.79
EBITDA Margin	-75.59%	-118.88%	-152.93%	7.99%	-
D&A For EBITDA	0.41	0.41	0.5	0.65	0.64
EBIT	-6.29	-7.5	-9.54	0.5	-11.43
EBIT Margin	-80.92%	-125.78%	-161.41%	3.48%	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.